The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.
 
Yucai Wang
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
Honoraria - Kite, a Gilead company (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); BeiGene (Inst); Genmab (Inst); Incyte (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Lilly (Inst); Loxo (Inst); TG Therapeutics (Inst)
Research Funding - Genentech (Inst); Genmab (Inst); Incyte (Inst); InnoCare (Inst); Loxo (Inst); MorphoSys (Inst); Novartis (Inst)
 
Melissa C. Larson
No Relationships to Disclose
 
Anita Kumar
Stock and Other Ownership Interests - Bridgebio
Consulting or Advisory Role - AstraZeneca/MedImmune; Celgene; Genentech; Janssen; Kite, a Gilead company; Loxo/Lilly
Research Funding - Abbvie/Genentech; Adaptive Biotechnologies; AstraZeneca/MedImmune; Celgene; Loxo/Lilly; Loxo/Lilly; Loxo/Lilly; Loxo/Lilly; MorphoSys/Incyte; Pharmacyclics; Seagen
 
Brian T Hill
Honoraria - Abbvie; AstraZeneca; Bayer; BeiGene; Celgene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis; Novartis; Pfizer; Pharmacyclics
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); Celgene (Inst); Genentech (Inst); Karyopharm Therapeutics (Inst); Kite/Gilead (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
David Alan Bond
Consulting or Advisory Role - Novartis; Nurix; TG Therapeutics
Research Funding - Genmab (Inst); Incyte (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Nurix (Inst)
 
Brad S. Kahl
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb; Genentech; Incyte; Janssen; Kite/Gilead; MEI Pharma; Roche; Seattle Genetics/Astellas; TG Therapeutics
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Genentech (Inst)
 
Alexey Valeryevich Danilov
Stock and Other Ownership Interests - Abbvie
Honoraria - Curio Science
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb; Genentech/Roche; Genmab; Incyte; Lilly; MEI Pharma; Merck; MorphoSys; Nurix; Pharmacyclics/Janssen; Prelude Therapeutics
Research Funding - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Cyclacel; Lilly; MEI Pharma; Nurix; Secura Bio; Takeda; TG Therapeutics
 
Reid Merryman
Consulting or Advisory Role - Abbvie; Alphasights; Alphasights; Bristol-Myers Squibb/Medarex; Epizyme; Intellia Therapeutics
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); Genmab (Inst); Merck (Inst)
 
Natalie Sophia Grover
Stock and Other Ownership Interests - Sangamo Therapeutics
Honoraria - ADC Therapeutics; Bristol Myers Squibb Foundation; Caribou Biosciences; Genentech; Kite, a Gilead company; Novartis; Ono Pharmaceutical; Seagen
Consulting or Advisory Role - Regeneron
Research Funding - Tessa Therapeutics
 
Aung M. Tun
No Relationships to Disclose
 
Sabarish Ram Ayyappan
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Fate Therapeutics; Intellisphere; iowa oncology society; Seagen; TG Therapeutics
Speakers' Bureau - Total CME
Research Funding - Genentech (Inst); Genmab (Inst); Regeneron (Inst)
 
Georgios Pongas
Stock and Other Ownership Interests - Amgen; crispr therapeutics; Lilly; mevox
Honoraria - Curio Science
 
Craig Anthony Portell
Consulting or Advisory Role - Abbvie; Aptitude Health; AstraZeneca; BeiGene; Carden Jennings; Curio Science; Janssen; Merck; Targeted Oncology
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Kite, a Gilead company (Inst); Loxo/Lilly (Inst); Merck (Inst); Prelude Therapeutics (Inst); Seagen (Inst); TG Therapeutics (Inst); VelosBio (Inst); Xencor (Inst)
 
Javier Munoz
Honoraria - Curio Science; Kyowa Hakko Kirin; OncView; Physicans' Education Resource; Seagen; Targeted Oncology
Consulting or Advisory Role - ADC Therapeutics; Alexion Pharmaceuticals; Aurobindo; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Debiopharm Group; Epizyme; Fosun Kite; Genentech; Genmab; Gilead Sciences; Innovent Biologics; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; MEI Pharma; MorphoSys; Novartis; Pfizer; Pharmacyclics; Seagen; Secura Bio; SERVIER; TG Therapeutics; Zodiac Pharma
Speakers' Bureau - Abbvie/Genentech; Acrotech Biopharma; AstraZeneca; Bayer; BeiGene; BeiGene; Celgene; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Pharmacyclics/Janssen; Seagen; Verastem
Research Funding - Celgene; Genentech/Abbvie; Incyte; Kite, a Gilead company; Millennium; Pharmacyclics/Janssen; Portola Pharmaceuticals; Seagen
 
Patrick Michael Reagan
Consulting or Advisory Role - Caribou Biosciences; Kite, a Gilead company
Research Funding - Genentech/Roche; Seagen
 
Muhamad Alhaj Moustafa
Consulting or Advisory Role - Abbvie; Abbvie; Acrotech Biopharma (Inst); Cancer Network; CSL Behring
 
Priyanka Avinash Pophali
Honoraria - Clinical Care Options; NCCN; Seagen
Consulting or Advisory Role - Seagen
Research Funding - Fate therapeutics (Inst); Marker Therapeutics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Seagen
 
Irl Brian Greenwell
Consulting or Advisory Role - Acrotech Biopharma; Janssen; Kite/Gilead; Kyowa Kirin International
Research Funding - Genentech/Abbvie
 
Jonathon Brett Cohen
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene; Janssen; Kite/Gilead; Loxo
Research Funding - AI Therapeutics (Inst); AstraZeneca (Inst); Bioinvent (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Janssen (Inst); Leukemia and Lymphoma Society (Inst); Loxo (Inst); Novartis (Inst); Takeda (Inst)
 
Peter Martin
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Daiichi Sankyo; Epizyme; Genentech; Janssen; Merck